511545-94-1

Usage

Uses

Used in Pharmaceutical Industry:
1-NONANOL, 9-[(4,4,5,5,5-PENTAFLUOROPENTYL)THIO] is used as a key intermediate in the synthesis of N-phenylcarboxamide derivatives, which are known for their antitumor properties. The incorporation of 1-NONANOL, 9-[(4,4,5,5,5-PENTAFLUOROPENTYL)THIO] into the molecular structure of N-phenylcarboxamide derivatives enhances their ability to target and inhibit the growth of cancer cells, making them potential candidates for cancer treatment.
In the preparation of these antitumor agents, 1-NONANOL, 9-[(4,4,5,5,5-PENTAFLUOROPENTYL)THIO] plays a crucial role in modulating the pharmacological properties of the final product, such as solubility, stability, and bioavailability. This allows for the development of more effective and targeted cancer therapies with fewer side effects.
Overall, 1-NONANOL, 9-[(4,4,5,5,5-PENTAFLUOROPENTYL)THIO] is a valuable chemical entity with significant potential in the field of medicinal chemistry, particularly for the development of novel antitumor agents. Its unique structure and properties contribute to the advancement of cancer treatment options and the improvement of patient outcomes.

Upstream product

• 55362-80-6 9-bromononan-1-ol 
• 148757-89-5 1-bromo-9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonane 
• 862700-61-6 thiobenzoic acid S-(4,4,5,5,5-pentafluoro-pentyl)ester 
• 101615-36-5 (4,4,5,5,5-pentafluoropentyl)iminothiocarbamate 4-methylbenzenesulfonate 
• 76334-30-0 9-iodononan-1-ol 
• 148043-73-6 4,4,5,5,5-pentafluorpentan-1-ol 
• 3937-56-2 1,9-Nonanediol 
• 252947-01-6 1-methanesulfonyloxy-4,4,5,5,5-pentafluoropentane 
• 511545-93-0 2-(9-hydroxynonyl)-2-thiopseudourea hydrobromide 

Downstream Products

• 1019971-17-5 (2S)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methyl-3-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyloxy]propanamide 
• 148757-89-5 1-bromo-9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonane 
• 415927-29-6 3-oxo-7α-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-4-en-17βyl acetate 
• 1239977-74-2 3-oxo-7β-[9-(4,4,5,5,5-pentafluoropentylsulfanyl)nonyl]estra-4-en-17βyl acetate 

Relevant academic research and scientific papers

Synthesis method of fulvestrant related substance

The invention relates to a synthesis method of a fulvestrant related substance. The structural formula of the fulvestrant related substance is shown as a formula I in the specification. The compound is prepared by taking 3,17-bis(tetrahydro-2H-pyran-2-yl)

Fulvestrant: From the laboratory to commercial-scale manufacture

The development of a commercial manufacturing process for fulvestrant (the active ingredient in 'Faslodex') is described. Key steps in the synthesis are stereoselective 1,6-addition of an organocuprate to a steroidal dienone followed by copper-mediated aromatisation of the A-ring. The strategy for dealing with noncrystalline intermediates is outlined. The production of drug substance of acceptable quality is critically dependent on limiting the formation of key impurities. The origin of these impurities is discussed, and measures to prevent or control their formation are described.

AMIDE DERIVATIVES

The invention concerns amide compounds of Formula (I) wherein groups R1, R2, R3, Q1, X, R4, R5, R6, and R7 are as defined in the description. The present invention als

STEROIDS FOR CANCER TREATMENT

The present invention relates to novel compounds which are 7α-substituted 17-alkylene-16α-hydroxy steroidal estrogens. This invention specifically relates to estrogen derivatives which contain 7α-substituents and which exhibit anti-estrogenic properties. The present invention also relates to use of said compounds as a medicament, and for the treatment of estrogen dependent disorders, a pharmaceutical composition comprising one or more of said compounds and a method of treatment.